Company | Page 64 of 71 | SpiritIndia.com

Radiography :: Eklin Medical Systems – industry’s first comprehensive digital radiographic positioning guide

Eklin Medical Systems, Inc., a leader in digital radiography (DR), PACS (Picture Archiving and Communication System) and Practice Information Management software (PIMS) for the veterinary care market, announced the introduction of a comprehensive positioning guide for capturing diagnostic equine digital radiographs. The guide features Sheika, a petite gray Arabian mare, who was rescued by the founders of Peninsula Equine Medical Center before she was about to be euthanized by her owner. The 65-page guide provides a quick reference resource for veterinarians and technicians when imaging a horse’s feet, pasterns, fetlocks, stifles, skull, cervical spine and other pertinent anatomy.

Pregnancy :: Next-generation contraceptive patch by Agile Therapeutics

Agile Therapeutics, a pharmaceutical development company focused on innovative transdermal products, is developing the next generation of contraceptive patches, one that is designed to deliver low doses of birth control hormones over a seven-day period.

Health :: New research to cut animal testing, uk

Researchers at The University of Manchester have been awarded 130,000 pounds to develop new techniques to reduce the need for animals in drug testing. Current checks to establish whether a new drug is carcinogenic can be inconclusive and require further testing on live animals to establish whether they are harmful or not.

Chikungunya :: Tramadol in chikungunya arthritis

Tramadol is an atypical opioid which is a centrally acting analgesic, used for treating moderate to severe pain. It is a synthetic agent, unrelated to other opioids, and appears to have actions on the GABAergic, noradrenergic and serotonergic systems. Some physicians are using tramadol in chikungunya arthritis.

ADHD :: NRP104 (lisdexamfetamine dimesylate) for the treatment of adhd

Shire plc announced that its collaborative partner New River Pharmaceuticals Inc. (Nasdaq: NRPH) has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NRP104 (lisdexamfetamine dimesylate), for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD).

Multiple Sclerosis :: Treatment of relapsing-remitting multiple sclerosis

UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) today announced a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter Phase II clinical trials next year.

Lung cancer :: New cancer drug AS1404 Antisoma extends life for lung cancer patients

Lung cancer patients treated with an experimental new drug lived over a third longer than patients treated with standard chemotherapy, according to data released. The phase II study, carried out by UK biotech company Antisoma plc, looked at 70 patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer.

Diabetes :: VeraLight outperforms fasting plasma glucose for diabetes screening

Researchers will report results of a follow-on study of the first non-invasive, diabetes-screening device that was able to significantly outperform the fasting plasma glucose (FPG) test and the A1C test for identifying diabetes and pre-diabetes in individuals with one or more known risk factors for the disease. Presented at the 2006 Scientific Assembly of the American Academy of Family Physicians, held here, the study showed a prototype of the device was able to identify 29% more patients than the FPG test and 17% more patients than the A1C test. Both the FPG and A1C are blood tests used to screen and evaluate patients at risk for diabetes.

Multiple Sclerosis :: Fty720 – fingolimod reduces multiple sclerosis symptoms

The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.

Schizophrenia :: Paliperidone ER for the treatment of schizophrenia

Johnson & Johnson Pharmaceutical Research & Development (JJPRD), L.L.C. announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding a New Drug Application (NDA) for paliperidone extended-release (ER) tablets for the treatment of schizophrenia.